Junlong Wu

No.130 At Dong'an Road
Xuhui, 200032, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications

Early matched comparison of a novel modular carina robotic platform and the da vinci system for robot-assisted radical prostatectomy.

Early matched comparison of a novel modular carina robotic platform and the da vinci system for robot-assisted radical prostatectomy.

Journal: Journal of robotic surgery
Published: May 29, 2026

Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial.

Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial.

Journal: European journal of nuclear medicine and molecular imaging
Published: February 20, 2026

First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC.

First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC.

Journal: BMC medicine
Published: November 28, 2025

Genomic Landscape and Clinical Relevance in Chinese Patients With Upper Tract Urothelial Carcinoma.

Genomic Landscape and Clinical Relevance in Chinese Patients With Upper Tract Urothelial Carcinoma.

Journal: JCO precision oncology
Published: July 25, 2025

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.

Journal: Signal transduction and targeted therapy
Published: June 10, 2025

Exploratory analysis of the molecular and genomic landscape of upper tract urothelial carcinoma using long-read sequencing.

Exploratory analysis of the molecular and genomic landscape of upper tract urothelial carcinoma using long-read sequencing.

Journal: BMC cancer
Published: May 25, 2025

Early clinical experience with the Carina robotic platform in urologic surgery.

Early clinical experience with the Carina robotic platform in urologic surgery.

Journal: BJUI compass
Published: March 02, 2025

Noninvasive Early Detection and Recurrence Monitoring for Non-Muscle-Invasive Bladder Cancer via Urine Tumor DNA: A Prospective Clinical Study.

Noninvasive Early Detection and Recurrence Monitoring for Non-Muscle-Invasive Bladder Cancer via Urine Tumor DNA: A Prospective Clinical Study.

Journal: MedComm
Published: February 10, 2025

Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with ≤5 conventional imaging defined distant metastases.

Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with ≤5 conventional imaging defined distant metastases.

Journal: European journal of nuclear medicine and molecular imaging
Published: February 03, 2025

Atlas of predicted protein complex structures across kingdoms.

Atlas of predicted protein complex structures across kingdoms.

Journal: Nature communications
Published: November 25, 2024

Comprehensive analysis of the LINC01122/TPD52 axis as a predictive biomarker in prostate adenocarcinoma.

Comprehensive analysis of the LINC01122/TPD52 axis as a predictive biomarker in prostate adenocarcinoma.

Journal: Scientific reports
Published: September 27, 2024

Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.

Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.

Journal: Cell reports. Medicine
Published: August 06, 2024
Showing 1-12 of 55

Last Updated: 09/26/2026